Related Experiment Video
Updated: Mar 25, 2026
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
11.2K
Is gliclazide a sulfonylurea with difference? A review in 2016
Awadhesh Kumar Singh1, Ritu Singh1
1a G.D Hospital & Diabetes Institute , Kolkata , West Bengal , India.
Expert Review of Clinical Pharmacology
|March 1, 2016
Summary
Sulfonylureas are popular for type 2 diabetes due to cost and efficacy. Gliclazide is preferred over other sulfonylureas, especially in elderly patients, due to safety and cardiovascular neutrality.
Area of Science:
- Endocrinology
- Pharmacology
- Internal Medicine
Background:
- Sulfonylureas (SUs) are widely prescribed for type 2 diabetes (T2DM) after metformin, valued for rapid glycemic control, established use, and low cost.
- Despite newer agents, SUs remain a common choice, though guidelines are shifting.
- The Dutch type 2 guidelines now recommend gliclazide specifically over the SU class.
Purpose of the Study:
- To review the efficacy and safety data of gliclazide.
- To compare gliclazide with other sulfonylureas (SUs) and oral anti-diabetic drugs.
- To evaluate the evidence supporting gliclazide's preference in T2DM treatment.
Main Methods:
- Literature review of published studies.
- Comparative analysis of efficacy and safety data.
- Focus on cardiovascular outcomes and elderly patient safety.
Main Results:
- Gliclazide is recognized for its safety profile, particularly in elderly patients.
- Emerging evidence suggests cardiovascular neutrality for gliclazide compared to other SUs.
- Gliclazide demonstrates comparable efficacy to other oral anti-diabetic agents.
Conclusions:
- Gliclazide emerges as a preferred second-line agent in T2DM management, especially for elderly individuals.
- Its safety and potential cardiovascular neutrality support its specific recommendation over other SUs.
- Further research may solidify gliclazide's role in T2DM treatment guidelines.
